Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

NCT04797000

Active Not RecruitingPhase 2

Sponsor: Novartis Pharmaceuticals

Conditions: Myelodysplastic Syndromes

Interventions: Eltrombopag, Placebo

Countries: Japan

This study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).

Eligibility overview

Sex: ALL

Age: 20 Years to 100 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Patients diagnosed with MDS according to the WHO classification revised 4th edition by investigator assessment with one of the following prognostic risk categories, based on the International

Prognostic Scoring System (IPSS-R):

* very low (0-1.5)
* low (2-3)
* intermediate risks (3.5-4.5) All following criteria for prognostic variables per IPSS-R should be met.
* Bone marrow blast \< 5% (per both investigator's assessment and central review)
* Cytogenetic very good, good or intermediate risk corresponding to IPSS-R

  * Platelet transfusion dependence
  * Refractory, intolerant to, or ineligible for MDS treatments
  * Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0 or 1

Exclusion Criteria:

* Patients with a history of prior administration of eltrombopag, romiplostim, or other TPO-RA
* Therapy-related MDS per WHO classification revised 4th edition
* MDS/myeloproliferative neoplasms including chronic myelomonocytic leukaemia per the WHO classification revised 4th edition
* MDS with excess blasts (EB) per WHO classification revised 4th edition
* Known history of IPSS-R high or very high risk MDS
* Currently receiving treatments for MDS (e.g., HMA, cyclosporine A (CsA) or lenalidomide). Supportive treatment with erythropoiesis-stimulating agents (ESAs) or erythroid mutation agent in anemic patients or granulocyte-colony stimulating factor (G-CSF) in patients with severe neutropenia and recurrent infections is allowed if at stable dosage for 3 months prior to screening and continued at the same dosing/schedule until the optimal dose of eltrombopag has been established.
* Patients scheduled for hematopoietic stem cell transplantation
* Bone marrow fibrosis that leads to an inability to aspirate adequate bone marrow sample
* Known thrombophilic risk factors (except in cases where potential benefits of participating in the study outweighed potential risks of thromboembolic events (TEE), as determined by the investigator)

Other protocol-defined inclusion/exclusion criteria may apply.
Locations (20)
  • Narita, Chiba, Japan
  • Kurume, Fukuoka, Japan
  • Ohtake, Hiroshima, Japan
  • Nishinomiya, Hyōgo, Japan
  • Kanazawa, Ishikawa-ken, Japan
  • Isehara, Kanagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Sendai, Miyagi, Japan
  • Nagasaki, Nagasaki, Japan
  • Sakai, Osaka, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Itabashi Ku, Tokyo, Japan
  • Shimonoseki, Yamaguchi, Japan
  • Aomori, Japan
  • Chiba, Japan
  • Fukushima, Japan
  • Gifu, Japan
  • Kumamoto, Japan
  • Osaka, Japan
  • Yamagata, Japan